
Century Therapeutics Reports Positive Q1 2025 Results and Advances in Cell Therapy Pipeline
PHILADELPHIA, PA — Century Therapeutics, Inc. (NASDAQ: IPSC) reported notable progress in Q1 2025, emphasizing advancements in its clinical and preclinical iPSC-derived cell therapy programs. Highlights include updates on the …
Century Therapeutics Reports Positive Q1 2025 Results and Advances in Cell Therapy Pipeline Read More